Agents for Epilepsy and Seizures
Customize your policy alerts
Sign up for meridian Policy MDN.PMN.352 alerts
Get alerted when Policy MDN.PMN.352 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization requirements, approval durations, and coverage criteria for specified antiepileptic agents for members covered by Meridian Health Plan (Medicaid line of business referenced). Affects providers requesting coverage for listed seizure/epilepsy medications.
No material clinical or coverage changes in this revision.
Coverage Criteria — Agents for Epilepsy and Seizures
Initial Therapy — Epilepsy or Seizures
Covered when ALL of the following are met
Approval duration 12 months; quantity limits may be overridden if medically necessary or for acute treatment where a second dose is needed for another location
Other diagnoses/indications
Covered when ONE of the following is met
See CP.PMN.255, CP.PMN.16, CP.PMN.53 as applicable
Continued Therapy
For continued therapy
Approval duration 12 months
Agent-specific dosing and limits
Dosing regimens and maximum doses provided for individual agents; coverage may be guided by these dosing recommendations.
chunk 27
chunk 28
chunk 29
chunk 30
chunk 31
chunk 33
chunk 34
chunk 35
chunks 36,37
Diazepam rescue product dosing and frequency limits
Dosing and frequency conditions for diazepam rescue products as provided in this section
Do not exceed 2 doses per single episode; do not treat more than 1 episode every 5 days or >5 episodes/month.
Refer to weight ranges per dose category and sprays per nostril as specified in labeling.
Available products and strengths
Product availability and formulations (informational)
Informational—used to confirm prescribed product strength and formulation.
Non‑FDA labeled uses that are not specifically addressed by this policy are excluded from coverage unless the provider supplies sufficient documentation of efficacy and safety consistent with the applicable off‑label use policy. Providers should follow the referenced off‑label or formulary/no‑coverage policies (e.g., CP.PMN.53, CP.PMN.255, CP.PMN.16) when a requested indication, age, or dosing is not listed in this policy.
Use of an agent is contraindicated in patients with a documented history of hypersensitivity to that drug or any of its components. Examples in this policy include clobazam, pregabalin, rufinamide, and midazolam, each of which lists hypersensitivity in its contraindications. Requests for agents in patients with known hypersensitivity may be denied.
Libervant buccal film dosing is weight‑banded for pediatric patients and allows up to 2 doses per single episode, with a second dose administered at least 4 hours after the first if needed. The policy treats these recommendations as coverage limits: do not treat more than 1 episode every 5 days or > 5 episodes per month using Libervant dosing as described.
For Medicaid members, when state Medicaid coverage provisions conflict with this clinical policy, the applicable state Medicaid provisions take precedence. Providers should consult the state Medicaid manual for any state‑specific coverage rules that supersede this policy.
Requests for non‑FDA approved indications that are not addressed in this policy may be denied unless the provider submits sufficient clinical documentation per the off‑label use policy. If the requested use is not listed in section III and criterion guidance does not apply, providers should follow CP.PMN.53 (off‑label) or the relevant formulary/no‑coverage policies to justify coverage.
Concomitant use of benzodiazepines with opioids carries a boxed warning for profound sedation, respiratory depression, coma, and death. This policy highlights that benzodiazepines (including midazolam and other listed agents) expose patients to risks of abuse, dependence, and withdrawal; combinations with opioids should be reviewed for safety and may affect coverage decisions.
Clinical documentation submitted with a prior authorization request must support a diagnosis of epilepsy or seizure disorder and demonstrate that the requested dosing does not exceed FDA‑approved limits (refer to section V for age‑ and weight‑specific dosing). For weight‑based rescue therapies such as Libervant or Valtoco, prescribers should document patient weight and the selected weight‑based dose, timing of prior doses (e.g., at least 4 hours between doses), and episode frequency to show compliance with the stated dosing and frequency limits.
Provider Actions, Prior Authorization, and Documentation Requirements
Prior authorization required (12‑month approvals)
Prior authorization is required for the agents listed in this policy; when criteria are met, approval is granted for a 12‑month period.
Confirm rescue therapy episode and monthly limits
Rescue therapies have specific episode and monthly dose limits that must be checked during authorization; for example, midazolam nasal spray is limited to 2 doses per single episode and no more than 1 episode every 3 days or >5 episodes per month.
- Libervant and Valtoco: limit of 2 doses per single episode; Libervant — do not treat more than 1 episode every 5 days or more than 5 episodes/month.
- Midazolam (Nayzilam): 1 spray (5 mg); if no response at 10 minutes a second spray may be given; do not treat more than 1 episode every 3 days or >5 episodes/month.
Match PA to product, dose, formulation and frequency limits
Prior authorization determinations must reflect the specific product, dose, formulation and documented adherence to stated dosing and frequency limits (for example, Libervant buccal film dosing by weight bands and Valtoco nasal spray dosing by age/weight and sprays per device).
- Document product and formulation (e.g., Libervant buccal film strength or Valtoco nasal spray concentration).
- Document dose and weight/age band used to select dose (Libervant weight bands; Valtoco mg/kg and spray count).
- Confirm requested supply does not exceed allowed frequency (e.g., intervals between episodes and per‑month caps).
Follow agent‑specific PA requirements in policy sections
This consolidated policy was adapted from multiple previously approved individual drug policies; specific prior authorization requirements and any agent‑specific criteria are contained in the applicable drug sections and must be followed.
- Refer to the individual drug sections in this policy (or the originating individual policies listed in the history) for any additional agent‑specific PA requirements.
Document prior use/contraindication to preferred alternatives
Therapeutic alternatives are listed in Appendix B and may be preferred agents; be prepared to document prior use or contraindications to alternatives if requesting a non‑preferred agent.
- Appendix B lists dosing regimens and dose limits for alternatives (e.g., diazepam rectal gel, phenytoin, carbamazepine, oxcarbazepine, phenobarbital, gabapentin, valproic acid, topiramate, levetiracetam).
Document therapeutic sequencing for syndromic epilepsy
For certain syndromic epilepsies, document therapeutic sequencing consistent with guideline recommendations (e.g., valproate or topiramate as first‑line for Dravet per NICE; clobazam and stiripentol as adjunctive options).
- If requesting agents for Dravet or LGS, include prior therapy history and reason for selecting the requested agent in relation to guideline‑recommended sequencing.
Document syndrome‑specific diagnosis and seizure context
When requesting agents for specific epilepsy syndromes (e.g., Lennox‑Gastaut, Dravet, tuberous sclerosis complex) include documentation supporting the syndrome diagnosis and seizure‑cluster characterization as applicable.
- Provide syndrome diagnosis, relevant clinical findings, and citation of guideline‑recommended therapies if applicable.
- For seizure‑cluster rescue agents, document frequency and pattern of clusters relative to the patient’s baseline.
Document pediatric weight and weight‑based dosing (Libervant/Valtoco)
For pediatric requests for Libervant or Valtoco, prescribers must document the patient's weight and the weight‑based dose selected; for Libervant and Valtoco a second dose may only be given after the minimum interval (about 4 hours) and dosing frequency caps must be documented.
- Record patient weight and specify which weight band was used to determine the Libervant buccal film dose.
- For Valtoco, document age/weight category, mg/kg dose and number of sprays/devices.
- Document timing of prior doses and that at least 4 hours elapsed before a second dose when applicable.
Document medical necessity per policy and coverage terms
Providers should document medical necessity consistent with this clinical policy and applicable coverage documents; coverage decisions remain subject to the member's benefit terms, exclusions and limitations.
- Include rationale for agent selection and prior therapy trials or contraindications to alternatives.
- Ensure documentation aligns with member’s coverage terms and any state Medicaid requirements.
Provide off‑label evidence when indication is non‑FDA
Requests for non‑FDA approved (off‑label) indications that are not addressed in this policy may be denied unless sufficient documentation per the off‑label use policy CP.PMN.53 (or other applicable off‑label procedures) is provided.
- If the indication is off‑label and not listed in section III, include supporting evidence of efficacy and safety per CP.PMN.53.
- If a recent label change within 6 months applies, follow the referenced formulary/non‑formulary policies instead.
Avoid requests when drug/component hypersensitivity is documented
Do not request coverage for patients with documented hypersensitivity to the specific drug or its ingredients; such contraindications (examples: clobazam, pregabalin, rufinamide, midazolam) may lead to denial.
- Review product contraindications for hypersensitivity and include allergy history in the request.
- If hypersensitivity is present, select an alternative therapy from Appendix B and document rationale.
Denial risk if requests exceed dosing frequency caps
Requests that exceed stated dosing frequency limits may be denied — examples include more than 2 doses per single episode or treating more than 1 episode every 5 days (Libervant) or >5 episodes/month.
- Libervant: do not approve treatment beyond 2 doses per episode, >1 episode every 5 days, or >5 episodes per month.
- Midazolam: do not approve treatment beyond 2 doses per episode or >5 episodes/month (and no more than 1 episode every 3 days).
Follow state Medicaid provisions for Medicaid members
State Medicaid coverage provisions take precedence for Medicaid members; when state Medicaid provisions conflict with this policy, follow the state Medicaid manual requirements.
- Check applicable state Medicaid manual provisions before submitting or appealing requests for Medicaid members.
Background and Context
Epilepsy and seizure disorders are managed primarily with antiepileptic drugs (AEDs). This policy supports prior authorization to ensure appropriate indication, dosing within FDA limits, and necessary safety monitoring. Certain agents have specific safety programs—for example, vigabatrin (Sabril) is associated with risk of permanent vision loss and is available only through a REMS program—and prescribers must follow those safety requirements when requesting coverage.
Definitions and Key Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.